Our mission is to organize educational programs that inform physicians about the latest medical and scientific advances in their field, help increase their knowledge and skills, and improve the outcomes for their patients. The programs will especially focus on the evolving key areas in diagnostics and therapeutics that concern Academic and practicing neurologists including new clinical criteria governing certain neurological diseases, updated state of the art neuro-therapeutics and pathogenesis, neuro-rehabiliation, neurology-imaging, updates on the most recent consensus criteria on disease classification, diagnosis, management and future perspectives on various rapidly evolving therapeutics or drugs for difficult to treat neurological disorders. Our faculties consist of renowned experts in the field, who will ensure that the information provided is accurate, evidence-based, supported by the medical literature and free of any commercial bias.
Prior to founding Neuro-EDU in 2019, Mrs. Williams and Mr. Blake were founding members and managing directors in two different neurology-focused healthcare organizations. The first organization, American Disease Management (ADIMA) was focused on the distribution of neurology-related specialty pharmacy medications. ADIMA was sold to a NASDAQ traded Prescription Benefits Management company in 2000. The second organization , Therapath Neuropathology, located in mid-town Manhattan, was focused exclusively on Neuropathology. Therapath Neuropathology was sold to a Private Equity Healthcare Firm and one of their portfolio companies in 2018. Both bring a myriad of expertise and years of experience in the field of neurology to Neuro-EDU.